In the relentless battle against emerging and endemic diseases, particularly the COVID-19 pandemic, scientists are leveraging cutting-edge technologies to revolutionize antibody research. This application note explores how the Beacon® System, with its optofluidic capabilities, is transforming functional analysis and early antibody identification.
The urgency of developing effective prevention and treatment strategies for diseases like COVID-19—rife with multiple mutations and immune escape tendencies of the SARS-CoV-2 virus—underscores the need for swift and robust antibody discovery methods. The Beacon System®, capable of screening tens of thousands of single B cells in a day, can rapidly identify potent antibodies, as demonstrated in critical studies related to COVID-19.
Through its optofluidic capabilities, the Beacon® system accelerates the screening of single B cells, leading to the identification of high-quality antibodies with unprecedented speed. The application note highlights the Beacon® system’s role in the discovery of antibodies crucial for AstraZeneca’s EvusheldTM antibody cocktail and its contribution to identifying broadly neutralizing antibodies against the ever-mutating SARS-CoV-2 virus. Furthermore, the Beacon® System's early detection of potent Omicron-neutralizing antibodies demonstrates its significance in staying ahead of emerging variants.
In the quest for next-generation therapeutic monoclonal antibodies (mAbs) and vaccines, Bruker's Beacon® System stands as a pivotal tool, empowering researchers to optimize and predict antibody responses and prepare against imminent disease threats.
Download this application note to learn:
- How rapid antibody screening with the Beacon® System Optofluidic can be applied to antibody identification and analysis
- Comparative screening efficiency and rapid lead identification
- How to identify broadly neutralizing antibodies for next-generation therapeutic mAbs and vaccines
- How to identify potent Omicron-neutralizing antibodies for COVID-19 early
